PYC’s growing U.S.-based team has deepened engagement with...

PYC’s growing U.S.-based team has deepened engagement with prominent healthcare industry investors along with a wide range of potential business development partners

There are two avenues for funding being pursued, a possible cornerstone investor, potentially explaining our stagnant share price at a target level for talks, and an investment by a potential biotech bank.
The longer we linger at these prices and the more funding conferences we participate in, the more likely it is that something is being prepared to move to the stock to the next level, triple our current price according to the CEO in his latest interview.


Both could be dependent on favourable larger animal data and, in conjunction, the revelation of the CNS candidate.
Since penetration deep into the brain was already achieved in trials earlier this year, positive data from larger animals of our ocular trials would pave the way to project a likley 50% success rate onto our CNS candidate.

Developments could unfold rather quickly from there and a price of
70 to 80 cents prior to listing on NASDAQ would be quite achievable.

all IMO